These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 9125539)

  • 1. Antibody mapping to domains of botulinum neurotoxin serotype A in the complexed and uncomplexed forms.
    Chen F; Kuziemko GM; Amersdorfer P; Wong C; Marks JD; Stevens RC
    Infect Immun; 1997 May; 65(5):1626-30. PubMed ID: 9125539
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Engineered domain-based assays to identify individual antibodies in oligoclonal combinations targeting the same protein.
    Meng Q; Garcia-Rodriguez C; Manzanarez G; Silberg MA; Conrad F; Bettencourt J; Pan X; Breece T; To R; Li M; Lee D; Thorner L; Tomic MT; Marks JD
    Anal Biochem; 2012 Nov; 430(2):141-50. PubMed ID: 22922799
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Epitope characterization and variable region sequence of f1-40, a high-affinity monoclonal antibody to botulinum neurotoxin type a (Hall strain).
    Scotcher MC; McGarvey JA; Johnson EA; Stanker LH
    PLoS One; 2009; 4(3):e4924. PubMed ID: 19290051
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Characterization of the epitope region of F1-2 and F1-5, two monoclonal antibodies to Botulinum neurotoxin type A.
    Scotcher MC; Johnson EA; Stanker LH
    Hybridoma (Larchmt); 2009 Oct; 28(5):315-25. PubMed ID: 19857112
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Fine and domain-level epitope mapping of botulinum neurotoxin type A neutralizing antibodies by yeast surface display.
    Levy R; Forsyth CM; LaPorte SL; Geren IN; Smith LA; Marks JD
    J Mol Biol; 2007 Jan; 365(1):196-210. PubMed ID: 17059824
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Domain-based assays of individual antibody concentrations in an oligoclonal combination targeting a single protein.
    Meng Q; Li M; Silberg MA; Conrad F; Bettencourt J; To R; Huang C; Ma J; Meyer K; Shimizu R; Cao L; Tomic MT; Marks JD
    Anal Biochem; 2012 Feb; 421(2):351-61. PubMed ID: 22037290
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mapping of protective and cross-reactive domains of the type A neurotoxin of Clostridium botulinum.
    Dertzbaugh MT; West MW
    Vaccine; 1996 Nov; 14(16):1538-44. PubMed ID: 9014296
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Recombinant proteins that trigger production of antibodies recognizing botulinum neurotoxin while not possessing sequences of this toxin.
    Zdanovsky A; Zdanovskaia M
    Toxicon; 2013 Jun; 67():63-70. PubMed ID: 23499926
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Epitope characterization of sero-specific monoclonal antibody to Clostridium botulinum neurotoxin type A.
    Corbett CR; Ballegeer E; Weedmark KA; Elias MD; Al-Saleem FH; Ancharski DM; Simpson LL; Berry JD
    Hybridoma (Larchmt); 2011 Dec; 30(6):503-10. PubMed ID: 22149274
    [TBL] [Abstract][Full Text] [Related]  

  • 10. High-affinity, protective antibodies to the binding domain of botulinum neurotoxin type A.
    Pless DD; Torres ER; Reinke EK; Bavari S
    Infect Immun; 2001 Jan; 69(1):570-4. PubMed ID: 11119555
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Regions of botulinum neurotoxin A light chain recognized by human anti-toxin antibodies from cervical dystonia patients immunoresistant to toxin treatment. The antigenic structure of the active toxin recognized by human antibodies.
    Atassi MZ; Dolimbek BZ; Jankovic J; Steward LE; Aoki KR
    Immunobiology; 2011 Jul; 216(7):782-92. PubMed ID: 21281977
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mapping of the antibody-binding regions on the HN-domain (residues 449-859) of botulinum neurotoxin A with antitoxin antibodies from four host species. Full profile of the continuous antigenic regions of the H-chain of botulinum neurotoxin A.
    Atassi MZ; Dolimbek BZ
    Protein J; 2004 Jan; 23(1):39-52. PubMed ID: 15115181
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Characterization of the monoclonal antibody response to botulinum neurotoxin type A in the complexed and uncomplexed forms.
    Zhao H; Nakamura K; Kohda T; Mukamoto M; Kozaki S
    Jpn J Infect Dis; 2012; 65(2):138-45. PubMed ID: 22446121
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Molecular characterization of murine humoral immune response to botulinum neurotoxin type A binding domain as assessed by using phage antibody libraries.
    Amersdorfer P; Wong C; Chen S; Smith T; Deshpande S; Sheridan R; Finnern R; Marks JD
    Infect Immun; 1997 Sep; 65(9):3743-52. PubMed ID: 9284147
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Genetic and immunological comparison of anti-botulinum type A antibodies from immune and non-immune human phage libraries.
    Amersdorfer P; Wong C; Smith T; Chen S; Deshpande S; Sheridan R; Marks JD
    Vaccine; 2002 Feb; 20(11-12):1640-8. PubMed ID: 11858873
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Translocation of botulinum neurotoxin serotype A and associated proteins across the intestinal epithelia.
    Lam TI; Stanker LH; Lee K; Jin R; Cheng LW
    Cell Microbiol; 2015 Aug; 17(8):1133-43. PubMed ID: 25640773
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Induction of an immune response by oral administration of recombinant botulinum toxin.
    Kiyatkin N; Maksymowych AB; Simpson LL
    Infect Immun; 1997 Nov; 65(11):4586-91. PubMed ID: 9353037
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Exchanging the minimal cell binding fragments of tetanus neurotoxin in botulinum neurotoxin A and B impacts their toxicity at the neuromuscular junction and central neurons.
    Höltje M; Schulze S; Strotmeier J; Mahrhold S; Richter K; Binz T; Bigalke H; Ahnert-Hilger G; Rummel A
    Toxicon; 2013 Dec; 75():108-21. PubMed ID: 23817019
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Neutralizing antibodies of botulinum neurotoxin serotype A screened from a fully synthetic human antibody phage display library.
    Yu R; Wang S; Yu YZ; Du WS; Yang F; Yu WY; Sun ZW
    J Biomol Screen; 2009 Sep; 14(8):991-8. PubMed ID: 19726786
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Binding activity and immunogenic characterization of recombinant C-terminal quarter and half of the heavy chain of botulinum neurotoxin serotype A.
    Yu YZ; Ma Y; Chen YX; Gong ZW; Wang S; Yu WY; Sun ZW
    Hum Vaccin; 2011 Oct; 7(10):1090-5. PubMed ID: 21941093
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.